FDA Advisory Committee Backs Approval Of Orphan Drug Without Controlled Clinical Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Patient experience with Orphan Europe's Carbaglu proves convincing, but panelists suggest registry to collect long-term safety data.
You may also be interested in...
FDA Approves Drug For Rare Disease Without Clinical Trial
Orphan Europe's Carbaglu approval was based on a retrospective analysis of case studies - but FDA has said it should not be viewed as a precedent.
FDA Approves Drug For Rare Disease Without Clinical Trial
Orphan Europe's Carbaglu approval was based on a retrospective analysis of case studies - but FDA has said it should not be viewed as a precedent.
Can An Orphan Drug Be Approved Without Clinical Trial?
FDA advisory committee will consider Orphan Europe's NDA for Carbaglu in NAGS deficiency, which is based on data from retrospective review of patient experience with carglumic acid